UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

 

FORM 20-F/A 

 

Amendment No. 2

 

|         |                                                                                                     |
|---------|-----------------------------------------------------------------------------------------------------|
| ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 |

 

OR

|         |                                                                                      |
|---------|--------------------------------------------------------------------------------------|
| ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

 

For the fiscal year ended December 31, 2018

 

OR

 

|         |                                                                                          |
|---------|------------------------------------------------------------------------------------------|
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

 

For the transition period from                      to                     

 

OR

|         |                                                                                             |
|---------|---------------------------------------------------------------------------------------------|
| ☐ | SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

 

Date of event requiring this shell company report                     

 

Commission file number 001-38205

 

ZAI LAB LIMITED

(Exact name of Registrant as specified in its charter)

 

 

N/A

(Translation of Registrant’s name into English)

 

Cayman Islands

(Jurisdiction of incorporation or organization)

 

4560 Jinke Road

Bldg. 1, Fourth Floor

Pudong

Shanghai, China 201210

(Address of principal executive offices)

 

Samantha Du

Chief Executive Officer

Zai Lab Limited

4560 Jinke Road

Bldg. 1, Fourth Floor

Pudong

Shanghai, China 201210

Telephone: +86 21 6163 2588

(Name, telephone, email and/or facsimile number and address of Company contact person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

|                                                                                                 |        |                                                                         |
|-------------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------|
| Title of each class                                                              |   | Name of each exchange on which registered |
| American depositary shares, each representing one

ordinary share, par value $0.00006 per share |   | Nasdaq Global Market                                                    |

 

Securities registered or to be registered pursuant to Section 12(g) of the Act:

 

None

(Title of Class)

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

 

None

(Title of Class)

 

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the Annual Report:

 

58,355,903 ordinary shares were issued and outstanding as of December 31, 2018

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    ☒  Yes   ☐  No

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.    ☐  Yes    ☒   No

 

Note—checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those sections.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    ☒    Yes    ☐   No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    ☒   Yes    ☐  No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definition of “accelerated filer and large accelerated filer” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

|                                         |         |        |                         |         |
|-----------------------------------------|---------|--------|-------------------------|---------|
| Large Accelerated Filer  | ☐ |   | Accelerated Filer  | ☒ |
| Non-Accelerated Filer                   | ☐ |   | Emerging Growth Company | ☒ |

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† pursuant to Section 13(a) of the Exchange Act.     ☒

 

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

|                |         |                                                                                                                     |         |                   |         |
|----------------|---------|---------------------------------------------------------------------------------------------------------------------|---------|-------------------|---------|
| U.S. GAAP | ☒ | International Financial Reporting Standards

as issued by the International Accounting

Standards Board   | ☐ | Other   | ☐ |

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.    ☐   Item 17    ☐   Item 18

If this is an Annual Report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    ☐   Yes    ☒   No

 

----

EXPLANATORY NOTE – EXHIBIT FILING ONLY

Zai Lab Limited (the “Company”) is filing this Amendment No. 2 (this “Amendment”) to its Annual Report on Form 20-F for the year ended December 31, 2018 (the “Form 20-F”), originally filed on March 29, 2019. This Amendment is an exhibit-only filing in response to comments received from the Securities and Exchange Commission regarding a request for confidential treatment of certain portions of Exhibit 10.15 originally filed with the Form 20-F. This Amendment is being filed solely to re-file Exhibit 10.15 based on Commission comments. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and principal financial officer are filed as exhibits to this Amendment. 

This Amendment is limited in scope to the items identified above and should be read in conjunction with the Form 20-F. This Amendment does not reflect events occurring after the filing of the Form 20-F and no revisions are being made to the Company’s financial statements pursuant to this Amendment. Other than the filing of the information identified above, this Amendment does not modify or update the disclosure in the Form 20-F in any way.

 

----

EXHIBIT INDEX 

 

|         |   |                                                                                                                                     |
|--------------|--------|------------------------------------------------------------------------------------------------------------------------------------------|
| Exhibit

No. |   | Description                                                                                                                              |
|         |   |
| 10.15*^  |   | License and Collaboration Agreement by and between Novocure Limited and Zai Lab (Shanghai) Co., Ltd. dated September 10, 2018            |
|         |   |                                                                                                                                     |
| 12.1*        |   | Certification of Chief Executive Officer Required by Rule 13a-14(a)                                                                      |
|         |   |                                                                                                                                     |
| 12.2*        |   | Certification of Chief Financial Officer Required by Rule 13a-14(a)                                                                      |
|         |   |                                                                                                                                     |
| 15.1**       |   | Certification of Chief Executive Officer Required by Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code |
|         |   |                                                                                                                                     |
| 15.2**       |   | Certification of Chief Financial Officer Required by Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code |

 

| * | Filed herewith |
|---|----------------|

 

| ** | Furnished herewith |
|----|--------------------|

 

| ^ | Confidential treatment has been requested as to certain portions, which portions have been omitted and submitted separately to the Securities and Exchange Commission. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

 

----

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

|                       |                 |        |                         |
|-----------------------|-----------------|--------|-------------------------|
|                  | ZAI LAB LIMITED |
|                  |            |   |                    |
|                  | By:             |   | /s/ Samantha Du         |
|                  | Name:           |   | Samantha Du             |
|                  | Title:          |   | Chief Executive Officer |
| Date: August 23, 2019 |            |   |                    |